Advertisement
Advertisement

MBX

MBX logo

MBX Biosciences, Inc. Common Stock

36.85
USD
Sponsored
+0.01
+0.03%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

36.84

-0.02
-0.05%

MBX Earnings Reports

Positive Surprise Ratio

MBX beat 4 of 5 last estimates.

80%

Next Report

Date of Next Report
Mar 17, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.64
Implied change from Q3 25 (Revenue/ EPS)
--
/
+1.59%
Implied change from Q4 24 (Revenue/ EPS)
--
/
+36.17%

MBX Biosciences, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, MBX reported earnings of -0.63 USD per share (EPS) for Q3 25, beating the estimate of -0.70 USD, resulting in a 10.09% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +9.71% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.64 USD, with revenue projected to reach -- USD, implying an increase of 1.59% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, MBX Biosciences, Inc. Common Stock reported EPS of -$0.63, beating estimates by 10.09%, and revenue of $0.00, 0% as expectations.
The stock price moved up 9.71%, changed from $22.55 before the earnings release to $24.74 the day after.
The next earning report is scheduled for Mar 17, 2026.
Based on 10 analysts, MBX Biosciences, Inc. Common Stock is expected to report EPS of -$0.64 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement